Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASX:MVP'
s EV-to-OCF Range Over the Past 10 Years
Min: -1460.4 Med: -0.71 Max: 2678.46
Current: 41.58
During the past 13 years, the highest EV-to-OCF of Medical Developments International was 2678.46. The lowest was -1460.40. And the median was -0.71.
ASX:MVP's EV-to-OCF is ranked worse than 86.01% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.825
vs ASX:MVP: 41.58
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medical Developments International (ASX:MVP) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medical Developments International's PE Ratio (TTM) for today is calculated as:
Medical Developments International's share price for today is A$0.48.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medical Developments International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medical Developments International EV-to-OCF Related Terms
Medical Developments International EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International EV-to-OCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Medical Developments International's EV-to-OCF falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (ASX:MVP) has a EV-to-OCF of 37.04 as of Aug. 05, 2026. According to the industry distribution chart, Medical Developments International ranks #867 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 86%.
Is Medical Developments International's EV-to-OCF too high?
Medical Developments International's current EV-to-OCF is 37.04. The Drug Manufacturers industry median EV-to-OCF is 10.83. Medical Developments International's value of 37.04 is 242.2% above this industry median. Based on the distribution chart, Medical Developments International ranks #867 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medical Developments International has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #867 out of 1008 companies for EV-to-OCF. This places Medical Developments International in the lower half of its industry. The industry median EV-to-OCF is 10.83. Medical Developments International's value of 37.04 is 242.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.83, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current EV-to-OCF of 37.04 is 242.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current EV-to-OCF is 37.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.63, compared to a current price of A$0.48 — trading 23.8% below its estimated fair value. The current EV-to-OCF is 37.04 and 242.2% above the Drug Manufacturers industry median of 10.83. Medical Developments International's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current EV-to-OCF is 37.04 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.48 is trading 23.8% below its estimated GF Value™ of A$0.63.
GuruFocus considers Medical Developments International to be Modestly Undervalued.
Key valuation signals for ASX:MVP:
EV-to-OCF: 37.04
GF Value™: A$0.63 vs. price of A$0.48 (23.8% below fair value)
Industry Position: 242.2% above the Drug Manufacturers median (#867 of 1008)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
48GF Score
Get the complete analysis for ASX:MVP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
